DT001

DT001 is a preclinical-stage small molecule new chemical entity (NCE) being developed by Delica Therapeutics. The compound is designed to address age-related diseases by targeting mechanisms associated with chronic inflammation, oxidative stress, and neurodegeneration. As a key asset in Delica's pipeline, DT001 aims to leverage neuroprotective and antioxidant properties to mitigate cellular damage and inflammatory signaling. While the specific molecular target remains undisclosed, the drug is positioned for applications in treating a range of inflammatory and neurodegenerative conditions, aligning with the company's focus on the biological hallmarks of aging.